Ascendis Pharma

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
12.86B
Market cap12.86B
Price-Earnings ratio
-49.56
Price-Earnings ratio-49.56
Dividend yield
Dividend yield
Average volume
753.07K
Average volume753.07K
High today
$211.75
High today$211.75
Low today
$205.79
Low today$205.79
Open price
$209.03
Open price$209.03
Volume
594.22K
Volume594.22K
52 Week high
$223.19
52 Week high$223.19
52 Week low
$118.03
52 Week low$118.03

Stock Snapshot

Ascendis Pharma(ASND) stock is priced at $210.49, giving the company a market capitalization of 12.86B. It carries a P/E multiple of -49.56.

During the trading session on 2025-11-22, Ascendis Pharma(ASND) shares reached a daily high of $211.75 and a low of $205.79. At a current price of $210.49, the stock is +2.3% higher than the low and still -0.6% under the high.

Trading activity shows a volume of 594.22K, compared to an average daily volume of 753.07K.

Over the past 52 weeks, Ascendis Pharma(ASND) stock has traded between a high of $223.19 and a low of $118.03.

Over the past 52 weeks, Ascendis Pharma(ASND) stock has traded between a high of $223.19 and a low of $118.03.

ASND News

TipRanks 5d
Ascendis Pharma initiated with an Outperform at Wolfe Research

Wolfe Research initiated coverage of Ascendis Pharma (ASND) with an Outperform rating and $255 price target Yorvipath is off to a “strong” launch and “the party...

TipRanks 5d
Ascendis Pharma publishes results from ApproaCH Trial in JAMA Pediatrics

Ascendis Pharma (ASND) announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial of investigational once-weekly...

Analyst ratings

100%

of 15 ratings
Buy
100%
Hold
0%
Sell
0%
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.